crane(CR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

CR crane

Market Closed 12-20 16:00:00 EST

152.80

+0.27

+0.18%

盘后152.80

+0.000.00%

16:20 EST

High154.20	Low150.48	Vol894.01K
Open151.01	D1 Closing152.53	Amplitude2.44%
Mkt Cap8.70B	Tradable Cap7.28B	Total Shares56.92M
T/O136.53M	T/O Rate1.88%	Tradable Shares47.65M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"CR","market":"US","secType":"STK","nameCN":"crane","latestPrice":152.8,"timestamp":1734728400000,"preClose":152.53,"halted":0,"volume":894009,"hourTrading":{"tag":"盘后","latestPrice":152.8,"preClose":152.8,"latestTime":"16:20 EST","volume":327632,"amount":50062461.716,"timestamp":1734729614995},"delay":0,"floatShares":47645025,"shares":56920000,"eps":4.522168,"marketStatus":"Market Closed","change":0.27,"latestTime":"12-20 16:00:00 EST","open":151.01,"high":154.2,"low":150.48,"amount":136526339.6226,"amplitude":0.024389,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":4.522168,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1734944400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":152.53,"dividendRate":0.005203,"preHourTrading":{"tag":"盘前","latestPrice":151.76,"preClose":152.53,"latestTime":"05:47 EST","volume":4,"amount":607.19,"timestamp":1734691634863},"postHourTrading":{"tag":"盘后","latestPrice":152.8,"preClose":152.8,"latestTime":"16:20 EST","volume":327632,"amount":50062461.716,"timestamp":1734729614995},"volumeRatio":3.691701438776623,"impliedVol":0.3343,"impliedVolPercentile":0.5119},"requestUrl":"/m/hq/s/CR/wiki","defaultTab":"wiki","newsList":[{"id":"2493542586","title":"New Strong Sell Stocks for December 20th","url":"https://stock-news.laohu8.com/highlight/detail?id=2493542586","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493542586?lang=en_us&edition=fundamental","pubTime":"2024-12-20 21:15","pubTimestamp":1734700500,"startTime":"0","endTime":"0","summary":"Here are three stocks added to the Zacks Rank #5  List today:. ICON ICLR is a provider of outsourced development and services to pharmaceutical, biotechnology, medical device and government and public health organizations. The Zacks Consensus Estimate for its current year earnings has been revised 7.3% downward over the last 60 days.BHP Group Limited BHP is one of the world's largest diversified resource companies with operations across several continents. The Zacks Consensus Estimate for its current year earnings has been revised 5.9% downward over the last 60 days.Crane Company CR is a manufacturer and seller of engineered industrial products in the United States, Canada, the United Kingdom, Continental Europe, and internationally. The Zacks Consensus Estimate for its current year earnings has been revised almost 5.7% downward over the last 60 days.Want the latest recommendations from Zacks Investment Research?Today, you can download 7 Best Stocks for the Next 30 Days. Click to get t","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/0Y9Pa17EWKE7g9B40qB7NQ--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/c1a5c7fadb2fecc08cc496de7c8904dd","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/0Y9Pa17EWKE7g9B40qB7NQ--~B/aD00MTM7dz02MjA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/c1a5c7fadb2fecc08cc496de7c8904dd"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/strong-sell-stocks-december-20th-131500996.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance_au","symbols":["LU0426412945.USD","ICLR","LU2324357040.USD","LU1267930573.SGD","BK4585","LU2362541273.HKD","LU0175139822.USD","LU0472753341.HKD","LU0029864427.USD","BHP","LU0057025933.USD","LU0528227936.USD","LU0426417589.USD","LU1043141396.HKD","LU0882574055.USD","BK4588","LU0289960550.SGD","LU0994945656.USD","LU1791710400.SGD","BK7511","LU1691799644.USD","CR","BK4168","LU0289739343.SGD","BK7507","LU1267930813.SGD","LU0289961442.SGD","LU0889566641.SGD","LU0187121727.USD","LU0310800379.SGD","BHP.AU","LU0114720955.EUR","LU2362540622.SGD","LU2362541513.USD","BK4161","LU0511384066.AUD","LU0792757196.USD","LU1804176565.USD","LU0708994859.HKD","LU0728928796.USD","LU1791710582.SGD","LU1043141123.HKD","LU1121112475.USD","LU0128525929.USD","BK4532","BK4121","LU1983260115.SGD","BK7095","LU2244417387.USD","LU0069063385.USD"],"gpt_icon":0},{"id":"2492595481","title":"Press Release: enGene Reports Full Year 2024 Financial Results and Provides a Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2492595481","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492595481?lang=en_us&edition=fundamental","pubTime":"2024-12-20 05:05","pubTimestamp":1734642300,"startTime":"0","endTime":"0","summary":"BLA filing for detalimogene in BCG-unresponsive NMIBC with CIS on track for mid-2026. All cohorts of the Phase 2 LEGEND study now recruiting under updated protocol. Additional preliminary data from pivotal cohort anticipated in 2H 2025. Cash, cash equivalents and marketable securities of $297.9 million provide runway into 2027. \"Having demonstrated a 71% anytime complete response rate in the preliminary data from the LEGEND study's pivotal cohort of BCG-unresponsive NMIBC patients, initiated three additional NMIBC patient cohorts, and raised an additional $60 million in funding, enGene is in a strong clinical and financial position as we close the year,\" said Ron Cooper, Chief Executive Officer of enGene. \"With trial recruitment open across all cohorts, the profile of detalimogene continues to become clearer and stronger and, with the protocol enhancements now in place, we look forward to sharing LEGEND study updates across all cohorts expected in the second half of 2025.\". LEGEND stud","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CTO","BK4161","BK4135","BCG","CR","ENGN","BK4160"],"gpt_icon":0},{"id":"2492453376","title":"US lawmakers reject Republican bill to avert government shutdown","url":"https://stock-news.laohu8.com/highlight/detail?id=2492453376","media":"CNA","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492453376?lang=en_us&edition=fundamental","pubTime":"2024-12-20 04:05","pubTimestamp":1734638700,"startTime":"0","endTime":"0","summary":"WASHINGTON:The US House of Representatives on Thursday  overwhelmingly rejected a Republican-led funding Bill aimed at averting a government shutdown, with federal agencies due to run out of cash on Friday night and cease operations starting this weekend.The contentious legislation would have suspended the country's borrowing limit for President-elect Donald Trump's first two years in office and dozens of debt hawks in the Republican ranks rebelled against their own leadership to sink the package.It was a defeat for the Republican leader, who with tech billionaire Elon Musk - his incoming \"efficiency czar\" - had thrown his weight behind the plan.The retooled version was considered under a fast-track method that required two-thirds support but Democrats had been clear that they would deny Republicans the votes they needed to make up for the rebels in their ranks and it failed to win even a straightforward majority.Republican House Speaker Mike Johnson has been facing criticism from all ","market":"us","thumbnail":"https://dam.mediacorp.sg/image/upload/s--mCsUpKBy--/c_fill,g_auto,h_468,w_830/fl_relative,g_south_east,l_one-cms:core:watermark:ap_data-1,w_0.1/f_auto,q_auto/v1/one-cms/core/congress_budget_22334.jpg?itok=rByVFH4T","type":0,"news_type":0,"thumbnails":["https://dam.mediacorp.sg/image/upload/s--mCsUpKBy--/c_fill,g_auto,h_468,w_830/fl_relative,g_south_east,l_one-cms:core:watermark:ap_data-1,w_0.1/f_auto,q_auto/v1/one-cms/core/congress_budget_22334.jpg?itok=rByVFH4T"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.channelnewsasia.com/world/us-lawmakers-reject-republican-bill-avert-government-shutdown-4817531","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"can_highlight","symbols":["CR","BK4161"],"gpt_icon":1},{"id":"2492179098","title":"Immix Biopharma Announces Positive U.S. Clinical Data From First Four Patients in NEXICART-2 U.S. Trial of sterically-optimized CAR-T NXC-201 in relapsed/refractory Light Chain (AL) Amyloidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2492179098","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492179098?lang=en_us&edition=fundamental","pubTime":"2024-12-19 22:35","pubTimestamp":1734618900,"startTime":"0","endTime":"0","summary":"Immix Biopharma, Inc. (Nasdaq:IMMX)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/19/2999975/0/en/Immix-Biopharma-Announces-Positive-U-S-Clinical-Data-From-First-Four-Patients-in-NEXICART-2-U-S-Trial-of-sterically-optimized-CAR-T-NXC-201-in-relapsed-refractory-Light-Chain-AL-Am.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4230","IE00B19Z4B17.USD","BK4572","BK4006","BK4161","IE0031619046.USD","ODD","BK4183","CRS","CAR","AL","IE0034390439.USD","LU2065731478.USD","BK4022","IE00B66KJ199.SGD","NXC","BK4104","CR","IE00B19Z6F94.USD","IE00B7SZL793.SGD"],"gpt_icon":0},{"id":"2492127098","title":"Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2492127098","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492127098?lang=en_us&edition=fundamental","pubTime":"2024-12-19 21:05","pubTimestamp":1734613500,"startTime":"0","endTime":"0","summary":"APOLLO study investigating MT-601 in patients with relapsed lymphoma: 78% of patients achieved objective response rates, with 44.4% demonstrating complete response (CR) MT-601 was observed to be well ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/19/2999831/0/en/Marker-Therapeutics-Provides-a-Clinical-Update-on-MT-601-in-Patients-with-Lymphoma.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4561","IE0031619046.USD","BK4588","BK4142","IE00B66KJ199.SGD","MT","IE00B7SZL793.SGD","BK4022","BK4585","LU2065731478.USD","CAR","BK4139","CR","BK4230","LU1718418525.SGD","CRS","IE00B19Z4B17.USD","BK4161","MAR","BK4006","LENZ"],"gpt_icon":0},{"id":"2492184756","title":"China Resources Pharmaceutical Boosts Stake in CR Boya","url":"https://stock-news.laohu8.com/highlight/detail?id=2492184756","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492184756?lang=en_us&edition=fundamental","pubTime":"2024-12-18 22:42","pubTimestamp":1734532933,"startTime":"0","endTime":"0","summary":"China Resources Pharmaceutical Group Ltd. (HK:3320) has released an update. China Resources Pharmaceutical Group Ltd. has increased its stake in CR...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/china-resources-pharmaceutical-boosts-stake-in-cr-boya?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/china-resources-pharmaceutical-boosts-stake-in-cr-boya?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4161","CR"],"gpt_icon":0},{"id":"2492186317","title":"Tapestry, Inc. Releases FY2024 Corporate Responsibility Report","url":"https://stock-news.laohu8.com/highlight/detail?id=2492186317","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492186317?lang=en_us&edition=fundamental","pubTime":"2024-12-18 21:00","pubTimestamp":1734526800,"startTime":"0","endTime":"0","summary":"NEW YORK, December 18, 2024----Tapestry, Inc. , a house of iconic accessories and lifestyle brands consisting of Coach, Kate Spade, and Stuart Weitzman, today released its Fiscal Year 2024  Corporate Responsibility  report. The report details the company’s progress and achievements in sustainability, social impact and community building over the past year. The company’s framework, The Fabric of Change, encapsulates its vision for a better-made future.\"We believe investing in our communities, people and sustainability initiatives drives innovation and long-term success and resilience for Tapestry and our portfolio of brands,\" said Joanne Crevoiserat, Chief Executive Officer of Tapestry, Inc. \"I am incredibly proud of the milestones our teams achieved in the last year, and we continue to see opportunities ahead.\". Leveraged innovation to be a more responsible and sustainable company. In FY2024, Tapestry’s Scope 1 and 2 GHG emissions were reduced by 84% compared to our FY2021 baseline. Th","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/tezAmNbmDcTvh9_oPOUo1A--~B/aD0yMDY7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/8718ee232a60e9d03e276c017334b76d","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/tezAmNbmDcTvh9_oPOUo1A--~B/aD0yMDY7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/8718ee232a60e9d03e276c017334b76d"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/tapestry-inc-releases-fy2024-corporate-130000202.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4516","LU0208291251.USD","BK4161","LU0052756011.USD","LU0310800965.SGD","BK4588","TPR","CR","LU0128525689.USD","LU0320765489.SGD","LU0070302665.USD","LU1267930227.SGD","GRO","BK4585","BK4202"],"gpt_icon":0},{"id":"2492925209","title":"China Resources Double-Crane Pharmaceutical Passes GMP Compliance for Sugammadex Sodium","url":"https://stock-news.laohu8.com/highlight/detail?id=2492925209","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492925209?lang=en_us&edition=fundamental","pubTime":"2024-12-18 12:28","pubTimestamp":1734496109,"startTime":"0","endTime":"0","summary":"China Resources Double-Crane Pharmaceutical (SHA:600062) passed the good manufacturing practice compliance inspection for its sugammadex sodium injection.Sugammadex sodium can be used to treat neuromu","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0028","BK0010","BK0185","BK0175","CR","BK4161","BK0188","600062","BK0239"],"gpt_icon":0},{"id":"2492959531","title":"Affimed Reports Positive Clinical Update on AFM24/Atezolizumab Combination Therapy in Non-Small Cell Lung Cancer (NSCLC)","url":"https://stock-news.laohu8.com/highlight/detail?id=2492959531","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492959531?lang=en_us&edition=fundamental","pubTime":"2024-12-17 19:30","pubTimestamp":1734435000,"startTime":"0","endTime":"0","summary":"In 33 heavily pretreated NSCLC EGFR wild-type (EGFRwt) patients the combination of AFM24 and atezolizumab shows an overall response rate (ORR) of 21% (6 confirmed responses, 1 response awaiting confir","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/17/2998078/0/en/Affimed-Reports-Positive-Clinical-Update-on-AFM24-Atezolizumab-Combination-Therapy-in-Non-Small-Cell-Lung-Cancer-NSCLC.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AE","BK4195","BK4588","BK4213","CR","BK4138","BK4599","LU0053666078.USD","L","FAS","PR","ALT","BK4139","BK4107","BK4211","OS","BK4585","PPS","BK4161","PFS","BK4097","LU1878469433.USD","AST"],"gpt_icon":0},{"id":"2491690725","title":"Crane Company Receives ‘Buy’ Rating as Aerospace & Electronics Segment Drives Growth and Strong Balance Sheet Prospects","url":"https://stock-news.laohu8.com/highlight/detail?id=2491690725","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491690725?lang=en_us&edition=fundamental","pubTime":"2024-12-16 23:05","pubTimestamp":1734361547,"startTime":"0","endTime":"0","summary":"Crane Company (CR – Research Report), the Industrials sector company, was revisited by a Wall Street analyst today. Analyst Matt Summerville from D...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/crane-company-receives-buy-rating-as-aerospace-electronics-segment-drives-growth-and-strong-balance-sheet-prospects?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/crane-company-receives-buy-rating-as-aerospace-electronics-segment-drives-growth-and-strong-balance-sheet-prospects?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CR"],"gpt_icon":0},{"id":"2491773692","title":"Journal of Clinical Oncology Publishes NXC-201 Positive Clinical Results in relapsed/refractory AL Amyloidosis","url":"https://stock-news.laohu8.com/highlight/detail?id=2491773692","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491773692?lang=en_us&edition=fundamental","pubTime":"2024-12-16 22:48","pubTimestamp":1734360480,"startTime":"0","endTime":"0","summary":"Chimeric antigen receptor T-cell (CAR-T) cell therapy NXC-201 is a novel approach to treat relapsed/refractory AL Amyloidosis NXC-201 demonstrated compelling clinical activity, rapid and deep complete","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/16/2997631/0/en/Journal-of-Clinical-Oncology-Publishes-NXC-201-Positive-Clinical-Results-in-relapsed-refractory-AL-Amyloidosis.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4183","BK4104","IE00B7SZL793.SGD","LU2065731478.USD","CRS","BK4230","NXC","CR","CAR","AL","BK4022","ODD","BK4161","BK4572","IE00B66KJ199.SGD","IE00B19Z6F94.USD","IE00B19Z4B17.USD","BK4006","IE0034390439.USD","IE0031619046.USD"],"gpt_icon":0},{"id":"2491693172","title":"Hiab enters into a strategic HIAB dealer agreement with Ring Power Utility | Truck | Crane in the US","url":"https://stock-news.laohu8.com/highlight/detail?id=2491693172","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491693172?lang=en_us&edition=fundamental","pubTime":"2024-12-16 21:00","pubTimestamp":1734354000,"startTime":"0","endTime":"0","summary":"CARGOTEC CORPORATION, PRESS RELEASE, 16 DECEMBER 2024 AT 3:00 PM EET. Hiab, part of Cargotec, has signed a strategic HIAB loader cranes dealer agreement with Ring Power Utility | Truck | Crane in the US. The agreement comprises HIAB loader cranes, as well as services.Founded in 2008, Ring Power Utility | Truck | Crane has grown into a leader in utility equipment, vocational trucks, and cranes, offering top-tier products from world-class brands and delivering innovative solutions, exceptional service, and lasting value through 11 U.S. locations.“Hiab is looking for future growth, and an important part of that is to further expand our leading position in the growing North American markets. The cooperation that we now embark on with Ring Power Utility | Truck | Crane will greatly support our ambitions in this,” saysPauliina Kunvik, SVP Sales & Services, Hiab USA. \"Ring Power Utility | Truck | Crane is strategically very well positioned in the US and their sales and services organisations ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/PDM_IhgueS2wUqxVlsEf_w--~B/aD00MDt3PTE5ODthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/794f6bc04115d42caf9ef72873ba235a","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/PDM_IhgueS2wUqxVlsEf_w--~B/aD00MDt3PTE5ODthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/794f6bc04115d42caf9ef72873ba235a"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/hiab-enters-strategic-hiab-dealer-130000311.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["PW","BK4161","BK4213","REI","CYJBY","CR","BK4234","CYJBF","BK4084"],"gpt_icon":0},{"id":"2491277693","title":"BioAtla Presented Data Characterizing Mutated KRAS Genotype and Clinical Outcomes in Patients with Advanced NSCLC Treated with Mecbotamab Vedotin (Mec-V), a CAB-AXL-ADC, at the IASLC 2024 Hot Topic in Basic & Translational Science Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2491277693","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491277693?lang=en_us&edition=fundamental","pubTime":"2024-12-16 21:00","pubTimestamp":1734354000,"startTime":"0","endTime":"0","summary":"Improved median overall survival (OS) for Mec-V treated patients with treatment-refractory non-small cell lung cancer (NSCLC) expressing mutated KRAS (mKRAS) as compared to Mec-V treated patient with ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2024/12/16/2997463/0/en/BioAtla-Presented-Data-Characterizing-Mutated-KRAS-Genotype-and-Clinical-Outcomes-in-Patients-with-Advanced-NSCLC-Treated-with-Mecbotamab-Vedotin-Mec-V-a-CAB-AXL-ADC-at-the-IASLC-2.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B7SZL793.SGD","AXL","BAS","CR","BK4097","BK4231","BK4161","AEIS","BK4157","ADC","IE00B19Z4B17.USD","IE0031619046.USD","OS","BK4080","IE00B66KJ199.SGD","BK4139","BCAB","BK4124","CAB"],"gpt_icon":0},{"id":"2491636493","title":"CR Double-Crane Pharma's Nine Drugs Chosen in China's Centralized Drug Bid; Shares Down 3%","url":"https://stock-news.laohu8.com/highlight/detail?id=2491636493","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491636493?lang=en_us&edition=fundamental","pubTime":"2024-12-16 12:58","pubTimestamp":1734325129,"startTime":"0","endTime":"0","summary":"China Resources Double-Crane Pharmaceutical's  nine drugs were selected for China's centralized drug procurement bid, according to a Shanghai Stock Exchange disclosure on Saturday.The drugs are sugammadex sodium injection, mirabegron extended-release tablets, phloroglucinol injection, potassium chloride injection, roxatidine acetate hydrochloride for injection, sodium lactate ringer's injection, sodium bicarbonate ringer's injection, epalrestat tablets, and apremilast tablets.The pharmaceutical company's amikacin sulfate injection, peramivir injection, and aminophylline injection also participated in the bidding but were not shortlisted.The company's shares dropped less than 3% in recent trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0010","BK0239","BK4161","BK0188","BK0175","BK0185","CR","BK0028","600062"],"gpt_icon":0},{"id":"2491059327","title":"Merck Receives Positive EU CHMP Opinion for WELIREG® (belzutifan) as Treatment for Adult Patients With Certain Types of Von Hippel-Lindau Disease-Associated Tumors and for Certain Previously Treated Adult Patients With Advanced Renal Cell Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2491059327","media":"Business Wire","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491059327?lang=en_us&edition=fundamental","pubTime":"2024-12-13 20:05","pubTimestamp":1734091500,"startTime":"0","endTime":"0","summary":"If approved, WELIREG would be the first and only oral hypoxia-inducible factor-2 alpha  inhibitor available for these patients in the European Union. Positive opinion granted based on data from the Phase 2 LITESPARK-004 trial and the Phase 3 LITESPARK-005 trial. RAHWAY, N.J., December 13, 2024----Merck , known as MSD outside of the United States and Canada, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use  adopted a positive opinion recommending the conditional approval of WELIREG , Merck’s oral hypoxia-inducible factor-2 alpha  inhibitor, as monotherapy for:. The treatment of adult patients with von Hippel-Lindau  disease who require therapy for associated, localized renal cell carcinoma , central nervous system  hemangioblastomas, or pancreatic neuroendocrine tumors , and for whom localized procedures are unsuitable;The CHMP recommendation in VHL disease-associated tumors is based on objective response rate  and duration of response ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/dbkt8gMdtdZ.AB5OqhyRjg--~B/aD0yMTc7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/2b71d7dbe02738d5c8e95b07ced3bfac","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/dbkt8gMdtdZ.AB5OqhyRjg--~B/aD0yMTc7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/2b71d7dbe02738d5c8e95b07ced3bfac"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/merck-receives-positive-eu-chmp-120500709.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LU0289739699.SGD","MRK","BK4534","IE00BLSP4239.USD","LU0965509283.SGD","BK4156","LU1057294990.SGD","LU1941712264.USD","CNS","CR","LU2361044865.SGD","LU0053666078.USD","LU1093756168.USD","LU0265550946.USD","LU1291159041.SGD","SG9999001176.USD","AEIS","SGXZ57979304.SGD","LU1066051498.USD","RCC","LU2089984988.USD","SG9999001440.SGD","LU1974910355.USD","SG9999002224.SGD","LU0965509101.SGD","IE0031619046.USD","SG9999014559.SGD","LU1066053197.SGD","LU2468319806.SGD","LU2361045086.USD","SG9999014567.USD","BK4135","IE00B66KJ199.SGD","IE00BN8TJ469.HKD","LU1934455863.HKD","CHMP","LU0106261372.USD","GRO","L","LU1066051225.USD","LU1934455277.USD","LU1989772923.USD","BK4588","PR","BK4213","LU1116320901.HKD","LU1989772840.SGD","LU0985320562.USD","LU0203345920.USD"],"gpt_icon":0},{"id":"2490138759","title":"100% of Patients Achieve Remission Within 30 Days in Cohort 1 of Bispecific Mipletamig Frontline AML Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2490138759","media":"ACCESSWIRE","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490138759?lang=en_us&edition=fundamental","pubTime":"2024-12-12 22:00","pubTimestamp":1734012000,"startTime":"0","endTime":"0","summary":"Two of three patients achieved both complete remission and MRD-negative status. High response rates observed in earlier studies continue in ongoing mipletamig trial. \"Achieving remission in all three Cohort 1 patients is highly encouraging, particularly when viewed alongside prior trial results. Notably, two of these three patients achieved MRD-negative status, a critical outcome indicating that even the most sensitive diagnostic methods detect no remaining cancer cells. This result is strongly associated with longer-lasting remissions and improved survival rates,\" said Dirk Huebner, MD, Chief Medical Officer at Aptevo. \"What makes these outcomes even more compelling is that one of the MRD-negative patients had a TP53 mutation, a subgroup known for its poor prognosis due to chemotherapy resistance, genetic instability, and overall treatment challenges. This growing body of data underscores mipletamig's p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/100-patients-achieve-remission-within-140000631.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["APVO","BK4139","CR","BK4161"],"gpt_icon":0},{"id":"2490099608","title":"China Resources Beer Partners with CR Mixc Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2490099608","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490099608?lang=en_us&edition=fundamental","pubTime":"2024-12-12 19:09","pubTimestamp":1734001789,"startTime":"0","endTime":"0","summary":"China Resources Beer (Holdings) Co (HK:0291) has released an update. China Resources Beer (Holdings) Co has announced a new framework agreement wit...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/china-resources-beer-partners-with-cr-mixc-group?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/china-resources-beer-partners-with-cr-mixc-group?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CR","BK4161"],"gpt_icon":0},{"id":"2490582220","title":"China Resources Double-Crane Pharmaceutical Gets Drug Registration for Neurological Disease Tablets","url":"https://stock-news.laohu8.com/highlight/detail?id=2490582220","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490582220?lang=en_us&edition=fundamental","pubTime":"2024-12-12 14:28","pubTimestamp":1733984925,"startTime":"0","endTime":"0","summary":"China Resources Double-Crane Pharmaceutical (SHA:600062) subsidiary Hunan Xiangzhong Pharmaceutical obtained a drug registration for its sodium valproate sustained-release tablets from China's drug ad","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["600062","BK0175","BK0188","BK0185","CR","BK4161","BK0010","BK0028","BK0239"],"gpt_icon":0},{"id":"2490854140","title":"ADC Therapeutics Announces Positive Initial Data from LOTIS-7 Clinical Trial Evaluating ZYNLONTA® in Combination with Bispecific Antibody in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2490854140","media":"PR Newswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490854140?lang=en_us&edition=fundamental","pubTime":"2024-12-11 20:30","pubTimestamp":1733920200,"startTime":"0","endTime":"0","summary":"ZYNLONTA in combination with glofitamab demonstrated clinically meaningful benefit with 94% best ORR and 72% CR rate. Safety data show no dose-limiting toxicities , no high-grade cytokine release syndrome  or high-grade immune effector cell-associated neurotoxicity syndrome  across all patients. LAUSANNE, Switzerland, Dec. 11, 2024 /PRNewswire/ -- ADC Therapeutics SA , a commercial-stage global leader and pioneer in the field of antibody drug conjugates , today announced positive initial data from the LOTIS-7 Phase 1b open-label clinical trial evaluating the safety and efficacy of ZYNLONTA in combination with the bispecific antibody glofitamab  in patients with relapsed or refractory diffuse large B-cell lymphoma .\"We are excited by the strong initial results observed with ZYNLONTA plus glofitamab in second line plus patients with relapsed or refractory DLBCL,\" said Mohamed Zaki, MD, PhD, Chief Medical Officer of ADC Therapeutics. \"We believe these data support our hypothesis that comb","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Et0V8U3X6l.Laaek.1Xhrg--~B/aD0yNTA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/b45d5be0d129d2f2b168ba1839a068c7","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Et0V8U3X6l.Laaek.1Xhrg--~B/aD0yNTA7dz00MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/b45d5be0d129d2f2b168ba1839a068c7"],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/adc-therapeutics-announces-positive-initial-123000966.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/adc-therapeutics-announces-positive-initial-123000966.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE0031619046.USD","LENZ","IE00B66KJ199.SGD","BK4139","ADC","PR","CR","CRS","BK4161","IE00B7SZL793.SGD","BK4231","GRO","BK4006","BK4213","ADCT","BK4505","BK4080","IE00B19Z4B17.USD"],"gpt_icon":0},{"id":"2490504528","title":"Incyte Late-Breaking Tafasitamab (Monjuvi®) Data at ASH 2024 Demonstrate Significantly Improved Progression-Free Survival in Patients with Relapsed or Refractory Follicular Lymphoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2490504528","media":"Business Wire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490504528?lang=en_us&edition=fundamental","pubTime":"2024-12-10 23:30","pubTimestamp":1733844600,"startTime":"0","endTime":"0","summary":"The pivotal Phase 3 inMIND trial met its primary endpoint of progression-free survival  and key secondary endpoints in patients with relapsed or refractory follicular lymphoma  treated with tafasitamab  in combination with lenalidomide and rituximab. Positive data featured in a late-breaking oral presentation at the 2024 American Society of Hematology  Annual Meeting support the planned U.S. filing of a supplemental Biologics License Application  for tafasitamab in FL by year-end 2024. Incyte to host virtual analyst and investor event on Thursday, December 12, 2024, from 4:00-5:00 p.m. ET to discuss key data presented at ASH. WILMINGTON, Del., December 10, 2024----Incyte  today announced additional results from the pivotal Phase 3 inMIND trial evaluating treatment with tafasitamab , a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, in combination with lenalidomide and rituximab compared with placebo plus lenalidomide and rituximab in patients with relapsed or refrac","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/3u2N6H22k_IlndsWGjtwyA--~B/aD0zNDk7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/63bb74c1cd3a14570cbe11fe3551c606","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/3u2N6H22k_IlndsWGjtwyA--~B/aD0zNDk7dz00ODA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/business-wire.com/63bb74c1cd3a14570cbe11fe3551c606"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/incyte-breaking-tafasitamab-monjuvi-data-153000049.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","BK4097","BK4109","LU2463526074.USD","CR","PFS","INCY","BK4139","BK4195","BK4094","BK4211","BK4532","BK4550","FL","BK4161","BK4585","ASH","OS"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.craneco.com","stockEarnings":[{"period":"1week","weight":-0.0738},{"period":"1month","weight":-0.1463},{"period":"3month","weight":0.0024},{"period":"6month","weight":0.0562},{"period":"1year","weight":0.34},{"period":"ytd","weight":0.2934}],"compareEarnings":[{"period":"1week","weight":-0.0216},{"period":"1month","weight":0.0011},{"period":"3month","weight":0.0403},{"period":"6month","weight":0.0857},{"period":"1year","weight":0.2506},{"period":"ytd","weight":0.2437}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Crane NXT, Co. focuses on payment and merchandising technologies. It indents to offer electronic equipment and associated software leveraging extensive, and proprietary core capabilities, including payment verification and authentication, as well as automation solutions, field service solutions, remote diagnostics, and productivity enhancing software solutions. The company is based in Stamford, Connecticut.","yearOnYearQuotes":[{"month":1,"riseRate":0.545455,"avgChangeRate":0.019214},{"month":2,"riseRate":0.727273,"avgChangeRate":0.037332},{"month":3,"riseRate":0.590909,"avgChangeRate":0.019088},{"month":4,"riseRate":0.6,"avgChangeRate":0.001456},{"month":5,"riseRate":0.622222,"avgChangeRate":0.007464},{"month":6,"riseRate":0.577778,"avgChangeRate":0.002848},{"month":7,"riseRate":0.577778,"avgChangeRate":0.003811},{"month":8,"riseRate":0.355556,"avgChangeRate":-0.008539},{"month":9,"riseRate":0.377778,"avgChangeRate":-0.02303},{"month":10,"riseRate":0.577778,"avgChangeRate":0.008898},{"month":11,"riseRate":0.555556,"avgChangeRate":0.027189},{"month":12,"riseRate":0.6,"avgChangeRate":0.018485}],"exchange":"ARCA","name":"crane","nameEN":"crane"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"crane(CR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest crane(CR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"crane,CR,crane股票,crane股票老虎,crane股票老虎国际,crane行情,crane股票行情,crane股价,crane股市,crane股票价格,crane股票交易,crane股票购买,crane股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"crane(CR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest crane(CR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction